NEXT GENERATION FACTORY
FOR NEXT GENERATION MEDICINE
Modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing
Astraveus is revolutionizing the field of CGT manufacturing with the Lakhesys™ platform, an end-to-end, cell foundry, that uses deep process optimization and single-use, microfluidic bioprocessors to deliver better results with reduced inputs.
By removing the need for large-scale infrastructure, reducing costs, and overcoming the logistical challenges typically associated with CGT manufacturing, Astraveus is seeking to transform patient access to these life-changing therapies.
SMALL IS POWERFUL
Therapeutic cells can multiply in the patient's body. This allows them to expand in vivo up to the amounts needed to obtain strong therapeutic effects.
Leveraging this characteristic, our microfluidic cell foundries allow us to optimize and miniaturize cellular therapies and their manufacturing. This way, minute amounts of resources are deployed without compromising efficacy.
As a result, the cost and environmental impact of these innovative therapies are drastically reduced.
The world’s first microfluidic cell foundry
With an end-to-end microfluidic manufacturing process, Lakhesys is unique.
At Lakhesys’ innovative core are microfluidic bioprocessors, which mimic organ perfusion and significantly accelerate the molecular exchanges needed to sustain and transform cells into potent therapeutic agents.
Once the process is optimized, Lakhesys allows us to produce massively in parallel, up to 100 minibatches simultaneously in a conventional size manufacturing room.
Lakhesys allows better results with fewer reduced inputs through increased mass transfer, precise control and minimized waste, resulting in higher quality products obtained at lower cost and reduced environmental impact.
Astraveus is supported by France and the European Union
Astraveus has received funding from the European Union's Horizon 2020 research and innovation programme, under grant agreement N° 850358, and from the French Minister of Education and Innovation and BPI France as part of i-Lab prize.
Lakhesys supports the development and manufacturing of most types of cell and gene therapies, including:
In healthy patients, T cells detect and kill sick cells. Cancer cells escape T cells recognition thanks to mutations.
CAR-T cells (T cells equipped with a Chimeric Antigen Receptor) are artificially hardcoded to recognize and kill cancer cells.
Multiple CAR-T therapies are commercially available, but their access is limited by low manufacturing throughput and high prices.
Hematopoietic stem cells (HSCs) are mothers to all blood cells including erythrocytes and lymphocytes.
Genetically engineering HSCs allows patients to produce blood cells with new or corrected functions.
Genetically engineered HSC have a proven potential to cure certain hemoglobinopathies and immune deficiencies.
DR JÉRÉMIE LAURENT
We're always interested in hearing from motivated, talented individuals.
Our current openings are below. If you don't find a suitable role, but believe you could be a strong addition to our team, please send your resume to email@example.com
PARTNERS & SUPPORTERS
We are based in Saint Louis, Hospital, downtown Paris.
1, Avenue Claude Vellefaux
Hôpital Saint-Louis, Centre MEARY
75010 Paris, France